Toxoplasma gondii is an intracellular protozoan parasite belonging from the phylum Apicomplexa, known for causing toxoplasmosis. The disease has a global presence, affecting about one-third of the world’s population. The parasite infects various intermediate hosts, including humans and other warm-blooded mammals, with cats serving as the definitive hosts. Its life cycle is complex, featuring a sexual phase in the definitive host and an asexual phase in intermediate hosts. Toxoplasmosis can leads severe neurologic, ocular, and systemic diseases in neonates and immunocompromised individuals. In immunocompetent individuals, the infection is typically asymptomatic, forming dormant tissue cysts in immune-privileged sites such as the muscles and brain. During pregnancy, toxoplasmosis poses significant health risks, potentially causing severe birth defects or miscarriage, and a major concern for immunocompromised hosts. Current control measures are inadequate, highlighting the need for effective vaccines. The initial host defense against T. gondii occurs at the intestinal mucosa, where cytokines and chemokines released by intestinal epithelial cells facilitate the migration of inflammatory cells, including macrophages, neutrophils, and dendritic cells. Developing a vaccine that can enhance this mucosal immunity is crucial for preventing toxoplasmosis. Therefore, the development of vaccines against T.gondii is a promising alternative mechanism to prevent toxoplasmosis. This review aims to present the current status of vaccine candidates against Toxoplasma gondii.